Nevertheless, the loss of BRCA1 in the majority of tumors in our study coupled with the increased expression of PARP in most of the cancers (discussed below) suggests that PARP upregulation may be a compensatory mechanism by cancer cells to withstand platinum-therapy-induced death. The gene discussed is BRCA1; the disease is cancer.